
Sign up to save your podcasts
Or


Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us through the company's on-site GMP facility, and she discusses the clinical experience to date. The therapy is already in a phase 3 study in Europe.
By BiotechTV4.3
66 ratings
Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us through the company's on-site GMP facility, and she discusses the clinical experience to date. The therapy is already in a phase 3 study in Europe.

3,222 Listeners

1,910 Listeners

124 Listeners

324 Listeners

61 Listeners

9,957 Listeners

86 Listeners

34 Listeners

353 Listeners

19 Listeners

60 Listeners

512 Listeners

41 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners

48 Listeners